31st Mar 2005 10:30
AstraZeneca PLC31 March 2005 Dealing by Directors Companies Act 1985 Sections 324/329 We hereby inform you that the interest of David R. Brennan, a Director of theCompany, in the American Depositary Shares (ADSs) of AstraZeneca PLC has changedas detailed below. One ADS equals one Ordinary Share. On 24 March 2005, Mr Brennan was granted a target award of 27,877 ADSs under theterms of the AstraZeneca US Executive Performance Share Plan (established in2000) at an award price of US$40.35 per ADS. The vesting date for this targetaward is 24 March 2008. The number of ADSs to which Mr Brennan may becomeunconditionally entitled on the vesting date will be determined by reference toAstraZeneca's Total Shareholder Return compared to that of other companies inthe Pharmaceutical Human Resources Association (PHRA) over the three yearperformance period. On 28 March 2005, Mr Brennan became unconditionally entitled to a final award of18,925 ADSs on the partial vesting of an original target award of 25,233 ADSs,which were awarded to him in March 2002 under the terms of the AstraZeneca USExecutive Performance Share Plan. Mr Brennan has ceased to have an interest inthe 6,308 ADSs of the original target award that did not vest. The closingprice of AstraZeneca ADSs on 28 March 2005 was US$39.62. On 28 March 2005, Mr Brennan purchased, on his own account, a notional interestin a further 11,358 ADSs to be held in the AstraZeneca US Executive DeferralPlan, a unitised stock fund established in 2000, in which Mr Brennan, in commonwith other participating US executives, is deemed to have a notional interest inADSs calculated by reference to the fund value and the closing price ofAstraZeneca ADSs. Following this purchase, Mr Brennan has a notional interestin 57,511 ADSs in the AstraZeneca US Executive Deferral Plan as at 28 March 2005based on that day's closing price of US$39.62. In total, Mr Brennan now has an interest in 172,364 AstraZeneca ADSs, includingthe notional interest in ADSs in the AstraZeneca US Executive Deferral Planreferred to above. G H R Musker Company Secretary 31 March 2005 This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Astrazeneca